Lauren T May

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4508037/publications.pdf

Version: 2024-02-01

50 papers	3,144 citations	218677 26 h-index	233421 45 g-index
51 all docs	51 docs citations	51 times ranked	3549 citing authors

#	Article	IF	Citations
1	Allosteric Modulation of G Proteinâ€“Coupled Receptors. Annual Review of Pharmacology and Toxicology, 2007, 47, 1-51.	9.4	615
2	Structure of the adenosine-bound human adenosine A1 receptorâ€“Gi complex. Nature, 2018, 558, 559-563.	27.8	274
3	Structure of the Adenosine A1 Receptor Reveals the Basis for Subtype Selectivity. Cell, 2017, 168, 867-877.e13.	28.9	237
4	The Effect of Allosteric Modulators on the Kinetics of Agonist-G Protein-Coupled Receptor Interactions in Single Living Cells. Molecular Pharmacology, 2010, 78, 511-523.	2.3	157
5	A kinetic view of GPCR allostery and biased agonism. Nature Chemical Biology, 2017, 13, 929-937.	8.0	126
6	Structure-Function Studies of Allosteric Agonism at M2Muscarinic Acetylcholine Receptors. Molecular Pharmacology, 2007, 72, 463-476.	2.3	105
7	Small-molecule-biased formyl peptide receptor agonist compound 17b protects against myocardial ischaemia-reperfusion injury in mice. Nature Communications, 2017, 8, 14232.	12.8	104
8	Dominant Negative G Proteins Enhance Formation and Purification of Agonist-GPCR-G Protein Complexes for Structure Determination. ACS Pharmacology and Translational Science, 2018, 1, 12-20.	4.9	96
9	Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4614-4619.	7.1	92
10	Positive allosteric mechanisms of adenosine A1 receptor-mediated analgesia. Nature, 2021, 597, 571-576.	27.8	84
11	Allosteric interactions across native adenosineâ€A ₃ receptor homodimers: quantification using singleâ€cell ligandâ€binding kinetics. FASEB Journal, 2011, 25, 3465-3476.	0.5	82
12	Allosteric modulators of G-protein-coupled receptors. Current Opinion in Pharmacology, 2003, 3, 551-556.	3.5	72
13	Allosteric Modulation of Endogenous Metabolites as an Avenue for Drug Discovery. Molecular Pharmacology, 2012, 82, 281-290.	2.3	69
14	Structural Basis for Binding of Allosteric Drug Leads in the Adenosine A1 Receptor. Scientific Reports, 2018, 8, 16836.	3.3	63
15	Cardioprotective potential of annexin-A1 mimetics in myocardial infarction. , 2015, 148, 47-65.		59
16	Quantification of adenosine A 1 receptor biased agonism: Implications for drug discovery. Biochemical Pharmacology, 2016, 99, 101-112.	4.4	58
17	Structure-based discovery of selective positive allosteric modulators of antagonists for the M ₂ muscarinic acetylcholine receptor. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2419-E2428.	7.1	57
18	Role of the Second Extracellular Loop of the Adenosine A₁ Receptor on Allosteric Modulator Binding, Signaling, and Cooperativity. Molecular Pharmacology, 2016, 90, 715-725.	2.3	56

#	Article	IF	Citations
19	A Positive Allosteric Modulator of the Adenosine A₁ Receptor Selectively Inhibits Primary Afferent Synaptic Transmission in a Neuropathic Pain Model. Molecular Pharmacology, 2015, 88, 460-468.	2.3	53
20	Extracellular Loop 2 of the Adenosine A1 Receptor Has a Key Role in Orthosteric Ligand Affinity and Agonist Efficacy. Molecular Pharmacology, 2016, 90, 703-714.	2.3	53
21	Ligand-Independent Adenosine A2B Receptor Constitutive Activity as a Promoter of Prostate Cancer Cell Proliferation. Journal of Pharmacology and Experimental Therapeutics, 2016, 357, 36-44.	2.5	50
22	New paradigms in adenosine receptor pharmacology: allostery, oligomerization and biased agonism. British Journal of Pharmacology, 2018, 175, 4036-4046.	5.4	49
23	Synthesis and Pharmacological Evaluation of Dual Acting Ligands Targeting the Adenosine A_{2A} and Dopamine D₂ Receptors for the Potential Treatment of Parkinsonâ€™s Disease. Journal of Medicinal Chemistry, 2015, 58, 718-738.	6.4	44
24	Targeting Adenosine Receptors for the Treatment of Cardiac Fibrosis. Frontiers in Pharmacology, 2017, 8, 243.	3.5	42
25	Structure-Activity Analysis of Biased Agonism at the Human Adenosine A₃ Receptor. Molecular Pharmacology, 2016, 90, 12-22.	2.3	37
26	Capadenoson, a clinically trialed partial adenosine A 1 receptor agonist, can stimulate adenosine A 2B receptor biased agonism. Biochemical Pharmacology, 2017, 135, 79-89.	4.4	37
27	The adenosine A2B G protein-coupled receptor: Recent advances and therapeutic implications. , 2019, 198, 20-33.		34
28	Regulation of M₂Muscarinic Acetylcholine Receptor Expression and Signaling by Prolonged Exposure to Allosteric Modulators. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 382-390.	2.5	31
29	The hybrid molecule, VCP746, is a potent adenosine A2B receptor agonist that stimulates anti-fibrotic signalling. Biochemical Pharmacology, 2016, 117, 46-56.	4.4	30
30	A Structureâ€“Activity Relationship Study of Bitopic N⁶-Substituted Adenosine Derivatives as Biased Adenosine A₁ Receptor Agonists. Journal of Medicinal Chemistry, 2018, 61, 2087-2103.	6.4	29
31	Biased agonism at adenosine receptors. Cellular Signalling, 2021, 82, 109954.	3.6	22
32	New Pharmacological Approaches to the Prevention of Myocardial Ischemia- Reperfusion Injury. Current Drug Targets, 2017, 18, 1689-1711.	2.1	22
33	Novel Irreversible Agonists Acting at the A₁ Adenosine Receptor. Journal of Medicinal Chemistry, 2016, 59, 11182-11194.	6.4	20
34	<scp>VCP</scp>746, a novel A₁ adenosine receptor biased agonist, reduces hypertrophy in a rat neonatal cardiac myocyte model. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 976-982.	1.9	20
35	Î± 1A -Adrenoceptors activate mTOR signalling and glucose uptake in cardiomyocytes. Biochemical Pharmacology, 2018, 148, 27-40.	4.4	20
36	Substituted Pyridazin-3(2H)-ones as Highly Potent and Biased Formyl Peptide Receptor Agonists. Journal of Medicinal Chemistry, 2019, 62, 5242-5248.	6.4	19

#	Article	IF	Citations
37	â€œSelectiveâ€•Class C G Protein-Coupled Receptor Modulators Are Neutral or Biased mGlu₅Allosteric Ligands. Molecular Pharmacology, 2018, 93, 504-514.	2.3	18
38	Formylpeptide receptor 2: Nomenclature, structure, signalling and translational perspectives: IUPHAR review 35. British Journal of Pharmacology, 2022, 179, 4617-4639.	5.4	18
39	Kinetic and system bias as drivers of metabotropic glutamate receptor 5 allosteric modulator pharmacology. Neuropharmacology, 2019, 149, 83-96.	4.1	17
40	Inhibition of the Proliferation of Human Lung Fibroblasts by Prostacyclin Receptor Agonists is Linked to a Sustained cAMP Signal in the Nucleus. Frontiers in Pharmacology, 2021, 12, 669227.	3.5	16
41	Biased agonism and allosteric modulation of metabotropic glutamate receptor 5. Clinical Science, 2018, 132, 2323-2338.	4.3	14
42	Effects of urea pretreatment on the binding properties of adenosine A1 receptors. British Journal of Pharmacology, 2005, 146, 1119-1129.	5.4	11
43	Development of Covalent, Clickable Probes for Adenosine A₁ and A₃ Receptors. Journal of Medicinal Chemistry, 2021, 64, 8161-8178.	6.4	7
44	Design, synthesis and evaluation of N6-substituted 2-aminoadenosine-5â€²-N-methylcarboxamides as A3 adenosine receptor agonists. MedChemComm, 2014, 5, 192-196.	3.4	6
45	Correspondence: Reply to â€˜Compound 17b and formyl peptide receptor biased agonism in relation to cardioprotective effects in ischaemia-reperfusion injuryâ€™. Nature Communications, 2018, 9, 530.	12.8	6
46	Development and Application of Subtype-Selective Fluorescent Antagonists for the Study of the Human Adenosine A₁ Receptor in Living Cells. Journal of Medicinal Chemistry, 2021, 64, 6670-6695.	6.4	6
47	Pharmacological Insights Into Safety and Efficacy Determinants for the Development of Adenosine Receptor Biased Agonists in the Treatment of Heart Failure. Frontiers in Pharmacology, 2021, 12, 628060.	3.5	5
48	Examining the Role of the Linker in Bitopic N⁶-Substituted Adenosine Derivatives Acting as Biased Adenosine A₁ Receptor Agonists. Journal of Medicinal Chemistry, 0, , .	6.4	1
49	Coincident activation of adenosine A1 receptors and metabotropic glutamate receptor 5 differentially influences signalling in primary brain cell cultures. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-1-117.	0.0	0
50	Coâ€activation of adenosine and glutamate receptors modulates signaling in primary brain cell cultures. FASEB Journal, 2018, 32, 555.18.	0.5	0